Video

CAR-Modified T Cell Therapy in ALL

For High-Definition, Click

Chimeric antigen receptor (CAR) T cell therapies are engineered through the genetic modification of an individual’s T cells to express a synthetic receptor that recognizes a particular antigen or protein, explains Dan Douer, MD. The process of transforming the T cells in the laboratory can take 4 to 5 weeks, which may be too long of a delay in the treatment of acute lymphoblastic leukemia, Douer suggests.

Severe cytokine release syndrome is the main adverse event with the CAR T cell therapies, Douer notes. This side effect occurs when a mixture of cytokines are released after activated T cells attack leukemic cells. Clinical presentation ranges from fever to septic shock. Other toxicities include neurologic side effects, such as seizures and altered mental status, notes Douer.

Similarities exist between CAR T-cell therapies and blinatumomab, explains Douer. In general, both therapies target CD19 and recruit the immune system to attack the cancer. Whether these two methods of treatment can be sequenced or combined remains unanswered, notes Mark R. Litzow, MD.

PD-1 and PD-L1 targeted monoclonal antibodies represent another potential immunotherapy strategy on the horizon for patients with B cell malignancies, believes Raoul Tibes, MD. These immune checkpoint inhibitors are approved in melanoma and lung cancer and are currently being evaluated in lymphoma, myelodysplastic syndromes, and other malignancies.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity